Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIM: Imatinib Dose Adjustment in CML
NCT01827930Phase 3Terminated
- Sponsor
- Institut Bergonié
- Start
- Jul 2009
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Institut Bergonié. Primary endpoint: Percentage of Patients Presenting a Decline of the BCR-ABL Transcript Rate at 12 Months From Baseline. Started Jul 2009; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01827930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827930.